Alpha Tau Medical (NASDAQ:DRTS) Hits New 1-Year High - Time to Buy?

Key Points

• Alpha Tau Medical shares reached a new 52-week high of $15.10, supported by several analyst price-target increases. The stock carries a “Moderate Buy” consensus rating, although the $12.80 consensus target is below its current price.
• The company reported a quarterly loss of $0.50 per share, missing the $0.14 consensus estimate, while revenue of $0.10 million also fell short of expectations.
• Insiders have recently reduced their holdings, with executives selling 132,871 shares worth approximately $1.56 million over 90 days; institutional investors own only 2.65% of the stock.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report)'s stock price hit a new 52-week high during trading on Thursday . The stock traded as high as $15.10 and last traded at $15.0340, with a volume of 251547 shares changing hands. The stock had previously closed at $14.96.

Analyst Upgrades and Downgrades

DRTS has been the topic of several analyst reports. Barclays increased their price target on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the stock an "overweight" rating in a research report on Thursday, June 4th. Weiss Ratings restated a "sell (d-)" rating on shares of Alpha Tau Medical in a research note on Friday, July 17th. HC Wainwright raised their target price on Alpha Tau Medical from $15.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. Piper Sandler lifted their price target on Alpha Tau Medical from $5.00 to $8.00 and gave the company a "neutral" rating in a research note on Tuesday, May 19th. Finally, Benchmark reissued a "buy" rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.80.

Alpha Tau Medical Stock Performance

The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -14.48 and a beta of 1.17. The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15. The stock's 50-day moving average is $12.74 and its 200-day moving average is $9.79.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.36). The business had revenue of $0.10 million for the quarter, compared to analysts' expectations of $0.14 million. On average, analysts predict that Alpha Tau Medical Ltd. will post -0.92 EPS for the current fiscal year.

Insider Transactions at Alpha Tau Medical

In other Alpha Tau Medical news, CFO Raphi Levy sold 32,500 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $10.83, for a total value of $351,975.00. Following the completion of the transaction, the chief financial officer directly owned 147,680 shares in the company, valued at approximately $1,599,374.40. This trade represents a 18.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders sold 132,871 shares of company stock valued at $1,562,208. 39.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. bought a new stake in Alpha Tau Medical during the 3rd quarter worth approximately $62,000. Bank of America Corp DE raised its stake in shares of Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock valued at $101,000 after acquiring an additional 21,677 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Alpha Tau Medical during the third quarter worth $170,000. Mariner LLC grew its stake in shares of Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company's stock worth $556,000 after purchasing an additional 80,129 shares during the last quarter. Finally, Trifecta Capital Advisors LLC bought a new stake in shares of Alpha Tau Medical in the fourth quarter worth $48,000. Institutional investors own 2.65% of the company's stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source